116
Participants
Start Date
November 30, 2010
Primary Completion Date
October 31, 2012
Study Completion Date
January 31, 2013
ISIS EIF4E Rx
800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
ISIS EIF4E Rx
1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
ISIS EIF4E Rx
(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8, and 15 of each 21 day cycle
Paclitaxel
200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle
Carboplatin
AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle
Achieve Clinical Research, Birmingham
University of Louisville - James Graham Brown Cancer Center, Louisville
Jewish Hospital & St. Mary's Healthcare, Louisville
Gabrail Cancer Center, Canton
Joliet Hematology Oncology Associates, Joliet
Genesis Cancer Center, Hot Springs
Little Rock Cancer Clinic, Little Rock
Highlands Oncology Group, Fayetteville
Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio
Kenmar Research Institute, Los Angeles
Non-State Medical Institution: Central Clinical Hospital #2 n.a. N.A. Semashko under OJSC Russian Railways, Chemotherapy Dept., Moscow
State Healthcare Institution: Ivanovo Regional Oncology Center, Chemotherapy Department, Ivanovo
State Medical Institution: Arkhangelsk Regional Clinical Oncology Center, Chemotherapy department, Arkhangelsk
State Healthcare Institution: Leningrad Regional Clinical Hospital, Thoracic Surgery Department, Saint Petersburg
"St. Petersburg State Healthcare Institution: City Clinical Oncology Center", Saint Petersburg
State Higher Educational Institution: St. Petersburg State Medica University n.a.I.P. Pavlov under the Federal Agency for Healthcare and Social Development, Pulmonology Research Institute, Saint Petersburg
State Institution: Samara Regional Clinical Oncology Center, Chemotherapy Department, Samara
State Therapeutical and Prophylactic Institution: Chelyabinsk Regional Clinical Oncology Center, Chemotherapy Department, Chelyabinsk
State Budget Healthcare Institution: Sverdlovsk Regional Oncology Center, Radiotherapy Department, Yekaterinburg
Koranyi National Institute of TBC and Pulmonology, Budapest
Semmelweis University Faculty of Medicine, Budapest
University of Debrecen, Medical and Health Science Center, Debrecen
Hospital for Thoracic Diseases of Csongrad County Local Governmental, Deszk
Bekes Country Pandy Kalman Hospital, Gyula
K. Dluski Provincial Specialist Hospital, Bialystok
Independent Public Teaching Hospital No. 4 In Lublin, Lublin
Idependent Public Tuberculosis an Lung Diseases Facilities, Olsztyn
Specialist Tuberculosis and Lung Diseases Hospitals, Rzeszów
Alojzy Pawelec Provincial Hospital of Lung Diseases, Wodzisław Śląski
Lead Sponsor
Ionis Pharmaceuticals, Inc.
INDUSTRY